a Department of Pharm Chem and QA , SVKM's Dr. Bhanuben Nanavati College of Pharmacy , Mumbai , India.
b Department of Pharmaceutics , SVKM's Dr. Bhanuben Nanavati College of Pharmacy , Mumbai , India.
Expert Opin Drug Deliv. 2019 May;16(5):525-538. doi: 10.1080/17425247.2019.1609937. Epub 2019 May 6.
The emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is a major health issue and continues to be a global health concern. Despite significant advancements in treatment modalities, ~1.6 million deaths worldwide occur due to TB infection. This is because of tuberculosis reservoirs in the alveoli making it a challenge for the formulation scientist to target this.
This review recent investigations on the forefront of pulmonary drug delivery for managing MDR-TB and XDR-TB. Novel delivery systems like liposomes, niosomes, employing carbohydrate, and -coated molecules via conjugation to selectively deliver the drugs to the lung TB reservoir via pulmonary administration are discussed.
Poor patient adherence to treatment due to side effects and extended therapeutic regimen leads to drug-resistant TB. Thus, it is essential to design novel strategies this issue by developing new chemical entities and/or new delivery systems for delivery to the lungs, consequently reducing the side effects, the frequency and the duration of treatment. Delivery of drugs to enhance the efficacy of new/existing anti-TB drugs to overcome the resistance and enhance patient compliance is underway.
耐多药结核病（MDR-TB）和广泛耐药结核病（XDR-TB）的出现是一个主要的健康问题，仍然是全球关注的健康问题。尽管在治疗方式上取得了重大进展，但全球仍有~160 万人因结核病感染而死亡。这是因为肺泡中的结核潜伏感染，这使得制剂科学家难以将其作为靶点。
本综述讨论了用于治疗耐多药和广泛耐药结核病的肺部药物输送的最新研究进展。通过肺部给药，新型的给药系统，如脂质体、非离子表面活性剂，利用糖和通过共轭修饰的分子，选择性地将药物递送到肺部的结核潜伏感染部位，这些系统正在被讨论。
由于副作用和延长的治疗方案，患者对治疗的依从性差导致了耐药性结核病。因此，通过开发新的化学实体和/或新的肺部给药系统来解决这一问题，从而减少副作用、治疗的频率和持续时间，设计新的策略至关重要。正在进行向肺部输送药物以提高新/现有抗结核药物的疗效，以克服耐药性并提高患者的依从性。
